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Abstract
Background: The present study examined the acute effects of a nutritional supplement intended
to improve adenosine triphosphate (ATP) concentrations on vertical jump height, isometric
strength of the leg extensors, leg extension endurance, and forearm flexion endurance.
Methods: Twenty-four healthy men (mean age ± SD = 23 ± 4 yrs, stature = 181 ± 7 cm, and body
mass = 82 ± 12 kg) volunteered to complete a familiarization trial plus 2 randomly-ordered
experimental trials separated by a 7-day washout period. Participants received either 6 (body mass
< 91 kg) or 8 (body mass ≥ 91 kg) tablets of the treatment (TR; 625 mg of adenylpyrophosphoric
acid and calcium pyruvate, 350.8 mg of cordyceps sinensis extract and yohimbine hydrochloride)
or placebo (PL; 980 mg of microcrystalline cellulose) 1 hour prior to the following tests:
countermovement vertical jump (CVJ), forearm flexion repetitions to exhaustion, isometric
maximal voluntary contractions (MVCs) of the leg extensors, and a 50-repetition maximal
concentric isokinetic leg extension endurance test.
Results: There were no differences between the TR and PL trials for CVJ height (P > 0.05),
isometric MVC peak torque (P > 0.05), maximal concentric isokinetic peak torque (P > 0.05),
percent decline during the leg extension endurance tests (P > 0.05), or repetitions to exhaustion
during the forearm flexion endurance tests (P > 0.05).
Conclusion: These findings indicated no improvements in the measured variables as a result of
ingesting this nutritional supplement. Future studies should examine whether chronic
supplementation or a loading period is necessary to observe any ergogenic effects of this
supplement.
Background
Nutritional supplements are commonly used by recrea-
tional and competitive athletes as ergogenic aids to
improve their physique and performance capabilities. For
example, creatine is a widely used nutritional supplement
that has been proven in multiple studies to increase skel-
etal muscle phosphocreatine and free creatine concentra-
tions, which may enhance the ability to sustain high
adenosine triphosphate (ATP) turnover rates during stren-
uous exercise [1]. As a result creatine supplementation
may delay neuromuscular fatigue [2], improve muscle
strength and power output [3], and increase muscle size
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[4]. The various purported benefits of nutritional supple-
ments, such as creatine [5], have subsequently led the
industry to explore the potential for alternative nutritional
supplements that may yield similar benefits (i.e., the next
'creatine'). Among such nutritional supplements are those
that are intended to directly increase ATP concentrations.
ATP is a purine nucleotide found in every human cell. The
most important function of ATP is to transfer energy [6].
Subsequently, ATP is regarded as the smallest form of
energy currency in living organisms [7]. When ATP is
hydrolyzed to adenosine diphosphate (ADP) and inor-
ganic phosphate (Pi), the terminal phosphate bond is bro-
ken and energy is liberated to drive biological processes
[7]. For human performance, the energy liberated by ATP
hydrolysis for muscle contraction is of paramount impor-
tance [8]. Skeletal muscle concentrations of ATP are rela-
tively limited, thus ATP must be continually resynthesized
[9]. Thus, in theory, any nutritional supplementation that
could increase ATP concentrations could also enhance
performance during high-intensity exercise [8].
Kichenin et al. [10] examined the effects of oral ATP sup-
plementation (5 mg/kg of [14C]ATP {1.85–2.29 GBq/
mmol} and [14C]adenosine {1.85–2.29 GBq/mmol}) in
rats. After 30 days of supplementation, there was an
increase in exportation of ATP from the gut and improved
adenosine uptake, ATP synthesis, and ATP transfer by red
cells [10]. Therefore, these findings [10] suggested that it
is possible to observe a positive biological response from
chronic oral ATP supplementation in rats. In humans, Jor-
dan et al. [8] administered 2 doses of an oral ATP supple-
ment (high dose = 225 mg; low dose = 150 mg) and
reported no differences in whole blood concentrations of
ATP immediately after the supplementation or after 14
days of supplementation. In addition, oral ATP supple-
mentation did not alter bench press strength or endur-
ance, and there were no changes in peak power, average
power, or total work during repeated 30-s Wingate tests
[8]. There was, however, an increase in bench press train-
ing volume observed after 14 days of oral ATP supplemen-
tation, which provided tentative evidence that the oral
ATP supplementation may be efficacious. Overall, the
findings of Jordan et al. [8] suggested that dosages of 225
mg or less of oral ATP supplementation may have been
too small to demonstrate any substantial performance
enhancement in humans. Besides Jordan et al. [8], we are
not aware of any other studies that have investigated the
effects of orally-administered ATP supplements in
humans. Therefore, the purpose of the present study was
to examine the acute effects of a commercially available
nutritional supplementation intended to improve ATP
concentrations on vertical jump height, isometric strength
of the leg extensors, leg extension endurance, and forearm
flexion endurance.
Methods
Participants
Twenty-four healthy men (mean age ± SD = 23 ± 4 yrs,
stature = 181 ± 7 cm, and body mass = 82 ± 12 kg) volun-
teered for this investigation. None of the participants
reported any current or ongoing neuromuscular diseases
or musculoskeletal problems specific to the ankle, knee,
or hip joints. Each participant completed a pre-exercise
health and exercise status questionnaire and signed a writ-
ten informed consent document. Twenty-one of 24 partic-
ipants reported engaging in 1–7 hours of aerobic exercise,
12 of 24 reported 1–8 hours of resistance exercise, and 18
of 24 reported 2–7 hours of recreational sports per week,
however, none of the participants were competitive ath-
letes.
Supplementation protocol
Two experimental supplements were used: a placebo (PL:
980 mg of microcrystalline cellulose) and a commercially
available treatment (TR; 625 mg of AdenylPyro-G™ for-
mula [adenylpyrophosphoric acid and calcium pyruvate],
350.8 mg of Cordy-cAMP™ formula [cordyceps sinensis
extract and yohimbine hydrochloride]) (5-TETRA, Epic
Nutrition, Jupiter, FL). Supplements were administered in
uniform containers and identifiable only by alphabetic
code to both the investigators and the subjects. In accord-
ance with the label recommendations, experimental trials
1 and 2 were performed 1 hour after the consumption of
either 6 (body mass < 91 kg) or 8 (body mass ≥ 91 kg) tab-
lets of the TR or PL. One week after each experimental
visit, each subject was asked if they have had any adverse
events since the previous visit. The experimental supple-
ments used during this investigation were donated.
Research design
This study was conducted with a double-blinded, pla-
cebo-controlled, crossover design. All participants com-
pleted 2 randomly-ordered experimental trials. The trials
were separated by a 7-day washout period and were per-
formed at the same time of day (± 2 hours). Seven days
prior to the first experimental trial, each participant vis-
ited the lab for a familiarization trial to practice the verti-
cal jumps, isometric and isokinetic leg extension muscle
actions, and the dynamic constant external resistance
(DCER) forearm flexion muscle actions. Each participant
was instructed to arrive for the experimental trials after a
4-hour fast so that the TR and PL tablets were adminis-
tered with water on an empty stomach in the laboratory
under the supervision of the investigators. Sixty minutes
after ingestion of either the TR or PL, the experimental
trial began with a 5-minute warm-up on a stationary cycle
ergometer (Monark 818E, Sweden) with a workload of 50
watts and cadence of 60–70 rpm. Following the warm-up,
subjects immediately completed the following tests: verti-
cal jump, DCER forearm flexion (i.e., biceps curls) repeti-Journal of the International Society of Sports Nutrition 2008, 5:3 http://www.jissn.com/content/5/1/3
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tions to exhaustion, isometric maximal voluntary
contractions (MVCs) of the leg extensors, and a 50-repeti-
tion isokinetic leg extension endurance test. All 4 assess-
ments were performed in the same fashion for both trials
with a 5-minute rest between each test.
Vertical jump
Four maximal countermovement vertical jump (CVJ) tri-
als where performed on a Just Jump™ mat (Probotics, Inc.,
Huntsville, AL) with a 1 minute rest period between trials.
The Just Jump™ mat calculated CVJ height (cm) based on
the flight time, which was the time that elapsed from the
instant the feet left the mat until landing. To complete the
CVJ trials, the participants stood on the mat with the feet
shoulder width apart and the hands on the hips. A rapid
descending quarter-squat countermovement was allowed
prior to the ascending launch, however, no step was taken.
The participants launched with both feet at the same time
and landed in the same position. Two separate one-way
ANOVAs were used to examine the systematic variation
among the 4 CVJ trials for the TR and PL sessions. CVJ
attempts 3 and 4 were greater than (P ≤ 0.05) attempts 1
and 2, however, there were no difference (P > 0.05)
between attempts 3 and 4. Therefore, the mean of CVJ tri-
als 3 and 4 was used as the representative CVJ score.
Isometric strength
Isometric torque for the right leg extensor muscles was
measured using a Biodex System 3 isokinetic dynamome-
ter (Biodex Medical Systems, Inc., Shirely, NY). The partic-
ipants were seated with restraining straps over the pelvis,
trunk, and contralateral thigh, and the lateral condyle of
the femur was aligned with the input axis of the
dynamometer in accordance with the Biodex User's Guide
(Biodex Pro Manual, Applications/Operations. Biodex
Medical Systems, Inc., Shirley, NY. 1998). All isometric
torque assessments were performed at a leg flexion angle
of 60° below the horizontal plane. Submaximal warm-up
trials preceded two 4-s isometric MVCs of the right leg
extensors. Participants were asked to produce as much
force as possible for 4-s, and strong verbal encouragement
was provided. Two minutes of rest was allowed between
each MVC trial. The torque signal from the dynamometer
was sampled at 1 KHz with an analog-to-digital converter
(DAQcard™-6036E, National Instruments, Austin, TX)
and custom software (LabVIEW Professional version 7.1,
National Instruments, Austin, TX) and stored on a per-
sonal computer for off-line analysis. The torque signal was
low-pass filtered (zero-phase 4th-order Butterworth filter)
with a 10 Hz cutoff, and peak MVC torque (PT) was calcu-
lated as the highest average torque value that occurred
during any 0.5-s duration within the 4-s MVC plateau.
Two separate dependent samples t  tests were used to
examine whether there was any systematic variability
between MVC trials 1 and 2 during the TR and PL sessions.
There were no differences (P > 0.05) between the PT val-
ues for MVC trials 1 and 2; therefore, both trials were aver-
aged and the mean was used as the representative PT
value.
Leg extension endurance
Five minutes after the isometric MVC trials, each partici-
pant completed the leg extension endurance test on the
Biodex System 3 isokinetic dynamometer based on the
procedures described by Housh, Housh, and deVries [11].
Three to five submaximal trials preceded 50 consecutive
maximal concentric isokinetic leg extension muscle
actions performed at 180°s-1 with the right leg. The active
range of motion was standardized from 90° to 180° of
knee flexion and extension, respectively, for each partici-
pant. As with the isometric MVCs, the torque signal was
sampled at 1 KHz and low-pass filtered (zero-phase 4th-
order Butterworth filter) with a 10 Hz cutoff. PT was deter-
mined for each of the 50 repetitions during the extension
muscle actions as the highest 10-ms average torque value
that occurred during each torque curve. Not all subjects
were able to complete all 50 repetitions; however, all sub-
jects did complete at least 48 repetitions. Therefore, the
first 48 repetitions were analyzed. The initial PT (IPT) was
calculated as the average of the 3 highest PT values that
occurred during the first 10 repetitions, whereas the final
PT (FPT) represented the average of the 3 lowest PT values
that occurred during the final 10 repetitions. Percent
decline was calculated with the following equation [11]:
Forearm flexion endurance
During the familiarization trial, maximal bilateral
strength of the forearm flexors was assessed with a stand-
ard one repetition maximum (1RM) procedure [12] in
order to establish the same relative submaximal load for
each subject for the TR and PL endurance tests. Each par-
ticipant performed a light warm-up of 5 – 10 repetitions
at approximately 50% of the estimated 1RM load. Follow-
ing a 1-min rest, the load was increased for a second
warm-up set of 3 – 5 repetitions. The load was then
increased for the first 1RM attempt. If successful, 3 – 5
minutes was allowed before the next attempt with a load
increase of 2.3 – 4.5 kg. This process continued until a
failed attempt occurred, and the last successful lift was
recorded as the representative 1RM score. The 1RM was
determined within 5 attempts.
Using the 1RM value, repetitions of a bilateral forearm
flexion exercise were performed until exhaustion with a
load of 70% of the 1RM on an externally-loaded preacher
curl machine (TDS™ Preacher Curl Machine, New York
Barebell, Elmira, NY). The total number of repetitions per-
PercentDecline
IPT FPT
IPT
=
−
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formed throughout the full range of motion was recorded
as the representative score. During the forearm flexion
muscle actions, the participants were required to remain
seated without leaning over the arm support. The partici-
pants were also required to keep their arms flat against the
arm support while the lateral epicondyles of ulna
remained aligned with the axis of rotation of the preacher
curl machine. During the TR and PL trials, each partici-
pant performed a warm-up at 50% of the 1RM for 5–8
repetitions 2 minutes prior to the endurance test.
Statistical analysis
Five separate paired-samples t tests were used to compare
the CVJ height, isometric PT of the leg extensors, percent
decline during the leg extension endurance test, and the
repetitions to exhaustion during the forearm flexion
endurance test scores for the TR vs. PL trials. A two-way
repeated measures ANOVA (trial [TR vs. PL] × repetition
[IPT vs. FPT]) was used to analyze the PT values during the
leg extension endurance test. When appropriate, follow-
up analyses included additional lower-order ANOVAs and
paired samples t tests. SPSS software (SPSS, Inc., version
12.0, Chicago, IL) was used for all statistical analyses. The
alpha level was set at P ≤ 0.05.
Results
There were no significant differences between the TR and
PL trials for CVJ height (P > 0.05), isometric peak torque
of the leg extensors (P > 0.05), percent decline during the
leg extension endurance tests (P > 0.05), or repetitions to
exhaustion during the forearm flexion endurance tests (P
> 0.05) (Table 1). For IPT and FPT, there was no two-way
interaction (trial × repetition, P > 0.05) or main effect for
trial (P > 0.05); however, there was a decrease (P ≤ 0.05)
in the marginal means for peak torque (collapsed across
trial) from IPT to FPT during the leg extension endurance
test.
Discussion
In the present study we found that the oral ATP supple-
ment, which was intended to improve performance, did
not improve vertical jump height, isometric strength of
the leg extensors, leg extension endurance, or forearm
flexion endurance. Jordan et al. [8] examined the effects of
different doses (high dose = 225 mg; low dose = 150 mg)
of an orally-administered ATP supplement on muscular
strength, anaerobic power, and anaerobic capacity. The
high dose of oral ATP taken 75 minutes prior to testing
resulted in an increase in bench press strength, which the
authors attributed to the presence of two outliers and
explained the improvement as a "...spurious change in the
observed treatment differences, rather than one attributa-
ble to oral adenosine 5'-triphosphate treatment" (p. 988).
There were no other changes reported for repetitions to
exhaustion at 70% of 1RM or total resistance training vol-
ume. Similarly, there were no observed changes for any of
the strength measurements in the low-dose group. Oral
ATP supplementation did not improve peak power out-
put, total work, or average power output during the two
30-s Wingate tests for either the high- or low-dose groups.
After 14 days of high-dose oral ATP supplementation,
total lifting volume increased by 22%, however, neither
muscular strength, anaerobic power, or anaerobic capac-
ity were influenced by the chronic supplementation [8].
The results of the present study extended the findings of
Jordan et al. [8] and suggested that a much higher acute
dose (5.9 – 7.8 g) of an oral ATP supplement did not
improve muscular strength, endurance, or power output
as measured by maximal voluntary isometric and isoki-
netic leg extension torque production, percent decline
during the leg extension endurance test, repetitions to
exhaustion for the biceps curl exercise, or CVJ height.
In previous studies, infusions of an ATP supplement have
been reported to increase extracellular and intracellular
ATP availability in rodent skeletal muscle by 116% and
50–70%, respectively [13,14]. However, Jordan et al. [8]
administered an oral ATP supplement to humans and
reported no differences in whole blood concentrations of
ATP following acute or chronic supplementation. Since
our findings suggested that an acute dose of this oral ATP
supplement did not improve exercise performance (con-
trary to the label claim), it is possible that it did not
increase ATP availability. Therefore, one hypothesis as to
why the current oral ATP did not improve exercise per-
formance is that the ingredients that were purported to
increase ATP availability did not survive the process of
digestion and absorption in the human gut [8]. A limita-
tion of the present study was that we did not extract tissue
or blood samples from these subjects, thus, we have no
direct evidence to suggest that this supplement altered
ATP concentrations. In contrast, the primary benefit of
Table 1: Mean (SEM) values for tests following the PL and TR
Test PL TR
Countermovement Vertical Jump Height (cm) 51.4 (1.6) 51.6 (1.3)
Isometric Leg Extensor Strength (Nm) 186.8 (10.0) 187.5 (9.6)
Leg Extensor Endurance Test (% decline) 64.9 (1.7) 64.6 (1.6)
Forearm Flexion Endurance Test (# of reps) 11.8 (0.4) 11.7 (0.4)Publish with BioMed Central    and   every 
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this applied study was that we tested (and ultimately
refuted) the label claim that this oral ATP supplement
improves performance. Since, at the time of this study, the
oral ATP supplement we tested was available on the mar-
ket, consumers may find our findings useful for making
an informed purchase. To elucidate the potential for oral
ATP supplementation to enhance performance, future
studies should examine whether the acute or chronic
ingestion of orally-administered ATP supplements
increase extracellular and/or intracellular ATP concentra-
tions, and subsequently, whether this translates into
improved performance measures.
Conclusion
In conclusion, there were no improvements in muscle
strength, power output, or endurance as a result of ingest-
ing 5.9 – 7.8 g of a nutritional supplement intended to
increase ATP concentrations and availability. Theoreti-
cally, increases in ATP availability should improve human
performance, however, lower doses of an oral ATP supple-
ment have not been shown to improve whole blood ATP
levels [8]. Although an acute dosage of this nutritional
supplement showed no beneficial effects on performance,
there were no detrimental effects either. In addition, no
adverse events were reported during the course of this
study, which suggested that acute doses may not be harm-
ful. It is unclear whether the chronic ingestion of this sup-
plement would result in any adverse effects. One
difference between the present study and the methods of
Jordan et al. [8] was that 60 minutes were allowed after
ingestion prior to the performance measures, whereas Jor-
dan et al. [8] allowed 75 minutes. Nevertheless, neither
study demonstrated any compelling results to suggest that
acute doses of orally-administered supplements that are
marketed to improve ATP availability actually improve
performance. Jordan et al. [8] did report an increase in
total resistance training volume following a 14-day sup-
plementation period. It is possible that a chronic loading
period of 14 days or longer is necessary to demonstrate
any meaningful ergogenic benefits. Therefore, future stud-
ies should examine whether a chronic loading period is
necessary to observe any ergogenic effects of nutritional
supplements that are marketed to improve ATP availabil-
ity.
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